Variability of human fasted venous plasma metabolomic profiles with tourniquet induced hemostasis

Sarita Devi1, Roshni M. Pasanna1, Nikhil Nadiger1, Santu Ghosh2, Anura V. Kurpad1 & Arpita Mukhopadhyay1*

Venous plasma metabolomics is a potent and highly sensitive tool for identifying and measuring metabolites of interest in human health and disease. Accurate and reproducible insights from such metabolomic studies require extreme care in removing preanalytical confounders; one of these is the duration of tourniquet application when drawing the venous blood sample. Using an untargeted plasma metabolomics approach, we evaluated the effect of varying durations of tourniquet application on the variability in plasma metabolite concentrations in five healthy female subjects. Tourniquet application introduced appreciable variation in the metabolite abundances: 73% of the identified metabolites had higher temporal variation compared to interindividual variation [Intra-Class Correlation (ICC) > 0.50]. As such, we recommend tourniquet application for minimal duration and to wait for 5 min with the needle in situ after removing the tourniquet, to reduce hemostasis-induced variability and false flags in interpretation.

Metabolomics, or the identification and measurement of metabolites in biological samples, has become an invaluable means for generating new knowledge in terms of markers for prognosis and diagnosis of human pathophysiology as well as of new leads in understanding causal pathways1–4. Of the various possible sources of samples from human subjects for metabolomic assessments, components of blood (plasma and serum), remain the most relevant and therefore, most studied type of sample5. However, unlike metabolomics performed with samples generated from in vitro or animal model experiments that are inherently less heterogeneous, using plasma or serum metabolomics as a tool in human translational research is subject to the inherent interindividual variability between subjects due to genetic and environmental factors and their interactions. An additional source of variation is pre-analytic factors. Controlling for such variability introducing pre-analytic factors would be key to improving reproducibility of high impact human metabolomic findings such as the use of sarcosine as a biomarker for progression of prostate cancer6,7. Here, fasting status, type of collection tube, presence of haemolysis, time taken and temperature of sample during processing, temperature and duration of storage of processed samples, and freeze–thaw cycles have been assessed8–12. Unknown and unaccounted for variation arising due to pre-analytic factors could lead to overestimation of interindividual variation or even intraindividual variation, if the samples have been collected at multiple time points in a longitudinal fashion. However, Aegueusop et al.13 reported remarkable stability of the human serum metabolome over a 4 weeks’ time period, when the samples were collected on 3 different days under stringently controlled conditions.

An additional, unstudied and potentially significant variation might arise from local tissue hemostasis during venous blood collection due to variable tourniquet application times and associated haemostasis. We could not identify any study that has investigated this effect on metabolomic readouts in the plasma. Therefore, we explored the effect of different durations of tourniquet-induced local hemostasis on fasted venous plasma metabolomic profiles of South Asian Indian women, for a deeper understanding of tourniquet-time related precautions required for reproducible untargeted human metabolomic studies. Our hypothesis was that the number of metabolites differing in abundance from the control, unrestricted blood flow condition would increase in step with the increased time of tourniquet-induced local hemostasis.

1Division of Nutrition, St. John’s Research Institute, St. John’s National Academy of Health Sciences, Sarjapur Road, Bangalore 560034, India. 2Department of Biostatistics, St. John’s Medical College and Hospital, St. John’s Research Institute, St. John’s National Academy of Health Sciences, Bangalore, India. *email: arpitam@sjri.res.in
Results
Socio-demographic characteristics, anthropometric measurements and metabolic profiles of the study participants are summarized in Table 1. All 05 subjects were apparently healthy, pre-menopausal females (age range 26.7–33.3 years). The BMI of the subjects ranged from normal to overweight (21.6–27.3 kg/m²). The subjects were normoglycemic (mean fasting glucose: 88.2 ± 5.2 mg/dL) and normotensive [mean systolic blood pressure (mmHg): 107.4 ± 5.8 and diastolic blood pressure (mmHg): 84.2 ± 7.4 respectively].

A total of 353 metabolites were identified in the study plasma samples by the Compound Discoverer software (version 3.1.0.305, ThermoFisher Scientific, Vanquish Flex Binary, Waltham, MA, USA). Since our primary aim was to identify and quantify the variation, if any, in the relative abundance of plasma metabolite across the 4 collection time points in all the study participants, we decomposed total variability into within time point variation (inter-individual variation) and between time point variation (temporal variation) (Supplementary Table 1). The temporal variation in the relative abundance of the identified metabolites between the 4 plasma collection time points, i.e., 1, 2 and 4 min after tying the tourniquet and NT (no tourniquet with sample collection 5 min after removal of the tourniquet) in 05 study participants is summarized in Fig. 1. In this, 73% of the identified metabolites had higher temporal variation compared to interindividual variation, as evident from Intra-Class Correlation (ICC) > 0.50, ICC being the proportion of temporal variation over total (temporal + inter-individual) variation. Interestingly, among all identified metabolites, 24 metabolites did not exhibit any temporal variation. The inter-individual variation for these 24 metabolites ranged between 11.4 to 98.1% (Supplementary Table 1). Box plots representing pareto-scaled intensities of three of these metabolites (pro-pro-pro, l-Isoleucine and l-Glutamic acid) and of three selected metabolites with high between timepoint temporal variability (1-Linoleoyl-sn-glycero-3-phosphocholine, Table 1.

| Subject characteristics and metabolic profile of the 05 study subjects. Data are mean ± SD. *Fasted blood sample. |
|---------------------------------------------------------------|
| **Mean ± SD** | **Age (years)** | 31.4 ± 2.7 |
| **BMI (kg/m²)** | 23.9 ± 2.4 |
| **Systolic blood pressure (mmHg)** | 107.4 ± 5.8 |
| **Diastolic blood pressure (mmHg)** | 84.2 ± 7.4 |
| **HbA1c (%)** | 5.4 ± 0.2 |
| **Fasting plasma glucose (mg/dL)** | 88.2 ± 5.2 |
| **Fasting serum insulin (mU/L)** | 10.5 ± 5.5 |
| **Serum cholesterol (mg/dL)** | 166.6 ± 19.6 |
| **Serum triglycerides (mg/dL)** | 78.6 ± 38.8 |
| **Serum creatinine (mg/dL)** | 0.7 ± 0.1 |

Figure 1. Distribution of temporal variability, measured by Intra-Class Correlation (ICC) of the 353 metabolites, identified as differentially abundant between the 4 collection time points [T1, T2, T4: 1, 2 and 4 min, respectively, after tying the tourniquet and NT (no tourniquet with sample collection 5 min after removal of the tourniquet)] in 05 study participants. The bold dark vertical line of the box-whisker plot superimposed on the density indicates the median ICC, the left and right sides of the rectangle are indicative of 25th and 75th percentiles and the whiskers measure the 95% confidence interval. The vertical dotted line at 0.50 ICC has been included to visualize the proportion of metabolites accounting for temporal variability > 50% of total variation of each metabolite.
1-Oleoyl-sn-glycero-3-phosphocholine and 1-Palmitoyl-sn-glycero-3-phosphocholine) is presented in Fig. 2. The raw and Pareto-scaled intensities of the 353 metabolites for all study subjects and sample collection time points is available in Supplementary Tables 2 and 3 respectively.

In order to further understand the effect of tourniquet-induced haemostasis on variability in metabolite abundances, we derived the interindividual variability of each metabolite at the 4 collection time points by coefficient variation (CV) calculated as the ratio of median absolute deviation (MAD) about median to median of the raw abundance of respective metabolites (Fig. 3). The CVs ranged up to 100% and when evaluated at each collection time point, the median CV was least at NT (15.11%, Table 2).

Discussion

Obtaining accurate and reproducible insights when using metabolomics tools in clinical research requires a critical evaluation of technical factors contributing to the overall variability of metabolomics profiles. We systematically interrogated the effect of duration of application of a tourniquet during collection of blood from healthy subjects, on the variability in metabolite concentrations using an untargeted metabolomics approach. We observed considerable temporal variability in relative abundance of the identified metabolites. The intra-class correlations, that measured the temporal variability in relation to the overall variability, were more than 0.50 for 73% of the identified metabolites (Fig. 1) and the mode was at ~ 0.90. Therefore, the duration of tourniquet application is an important factor that induces variability in measurement of abundance of the metabolites.

The inter-individual variation in metabolite abundances was higher amongst the metabolites with least temporal variation compared to those with highest temporal variation. This is plausible in light of the observation that amongst the 24 metabolites without any temporal variation were sesamex (a synergist for insecticides)\textsuperscript{14}, valdecoxib (a non-steroidal anti-inflammatory drug)\textsuperscript{15} and vanillin (primary component of vanilla bean extract)\textsuperscript{16}. These are exogenous metabolites, whose presence in the plasma is likely indicative of an individual’s consumption/exposure to the relevant exogenous sources.

With regard to time point of blood collection to minimize introducing variation due to tying of the tourniquet, the ideal situation would be to not use the tourniquet at all. However, considering the need for using the tourniquet to find the vein for blood collection in group of subjects where finding the vein is otherwise difficult, the duration of tourniquet application should be minimal and one should wait for 5 min with the needle in situ after removing the tourniquet, before blood sampling. As a rule, the shorter the duration of application of tourniquet, the better the accuracy in the measurement of metabolites.

A strength of our study is that we minimized inter-individual variation in plasma metabolomic profiles by carefully including subjects as similar to each other as possible, in terms of age (range 26.7–33.3 years), sex (all pre-menopausal females), ethnicity (South Asian Indian) and geographical location (Bangalore, India), as well as by collecting all samples within a one-hour time period in the morning, after a pre-defined fasting time period (11–12 h) These factors have been earlier reported to contribute to variability in human blood (plasma/serum) metabolomic profiles (age\textsuperscript{17–20}, sex\textsuperscript{19,20}, geographical location\textsuperscript{21–23}, fasting/mealtime\textsuperscript{24} and time of day...
when sample is collected\(^2\)). The small number of participants, with blood sampling at relatively few discrete time points, are limitations.

To conclude, for untargeted human plasma metabolomics studies, we recommend that blood should be collected without the application of a tourniquet for needle insertion. If this is needed, for example, when finding a vein is difficult, blood should be collected within 1 min of applying the tourniquet; if not, blood should be collected from the in situ needle at least 5 min after removing the tourniquet. With common sense, we also recommend making other a priori decisions on the exact standard operating procedure for the subject’s fasting/fed state, duration of fasting, timing of the day for collection of sample, type of sample collection tubes, duration of tourniquet application during sample collection, time–temperature-duration of storing the samples before processing, steps of sample processing including sample aliquot sizes to minimize freeze–thaw cycles, time–temperature-duration of storing the samples after processing and before freezing, duration of sample storage under frozen condition, number of permissible freeze–thaw cycles and also of the steps for sample processing after thawing, for metabolomics analysis, at the start of a study. A uniform, practical and rigid standard operating

### Table 2. Distribution of interindividual variability of metabolite abundance of the 353 metabolites, measured as the Coefficient of Variations (CVs) by collection time points [T1, T2, T4: 1, 2 and 4 min, respectively, after tying the tourniquet and NT (no tourniquet with collection 5 min after removal of the tourniquet)] in 05 study participants. The CVs were calculated as the ratio of median absolute deviation about median to median of the unscaled abundance (peak intensities) of respective metabolites. T1, T2, T4 are 1, 2 and 4 min respectively, of time elapsed after tying the tourniquet; NT is no tourniquet, where blood sample collection occurred 5 min after removal of the tourniquet.

| Sample collection time point | N  | Mean  | Median | SD   | Quartile 1 | Quartile 3 |
|-----------------------------|----|-------|--------|------|------------|------------|
| NT                          | 353| 22.58 | 15.09  | 20.17| 8.01       | 31.12      |
| T1                          | 353| 28.28 | 20.88  | 22.20| 11.88      | 40.54      |
| T2                          | 353| 27.49 | 19.61  | 24.36| 10.17      | 36.00      |
| T4                          | 353| 28.74 | 20.56  | 23.47| 11.46      | 38.88      |

**Figure 3.** The coefficient variation (CV) (representing inter-individual variability) of each metabolite at four sample collection time points [T1, T2, T4: 1, 2 and 4 min, respectively, after tying the tourniquet and NT (no tourniquet with collection 5 min after removal of the tourniquet)] in 05 study participants. The CVs were calculated as the ratio of median absolute deviation about median to median of the unscaled abundance (peak intensities) of respective metabolites and plotted for all 353 metabolites, identified as differentially abundant between the 4 collection time points (a) and as box-whisker plot (b) for each of the 4 collection time points summarizing the same feature by more interpretable manner. The bold dark horizontal line of the box-whisker plot indicates the median CV, the top and bottom ends of the rectangle are indicative of 25th and 75th percentiles and the whiskers measure the 95% confidence interval.
procedure that addresses these variability-inducing factors is a prerequisite for improving reproducibility and therefore, the relevance of plasma or serum metabolomics as a tool for interrogating human health and disease.

**Methods**

**Study design and inclusion criteria.** Apparently healthy female subjects (18–60 year old) volunteering to participate in the study were recruited at the Division of Nutrition, St. John’s Research Institute, St. John’s Medical College and Hospital, Bangalore. Exclusion criteria were: age outside 18–60 years range, not willing to participate in the study, were participating in other studies, had tested positive for hepatitis (HBSAg) or HIV, needed chronic or daily medical therapy (connective tissue diseases, inflammatory bowel disease, active tuberculosis, symptomatic heart disease), had serious pre-existing clinical conditions.

**Ethical approval and informed consent.** Ethical approval for the study had been sought and obtained from the Institutional Ethics Committee of St. John’s Medical College and Hospital, Bangalore. Explanation of the study protocol was done in the language understood by the participants. Informed, signed consent from the participants was obtained at recruitment. All relevant guidelines and regulations were followed while carrying out the study protocol.

**Socio-demographic data and medical history.** Well-structured questionnaires were provided to the participants and explained by trained study personnel for obtaining detailed socio-demographic data. Information on recent medical history (3 months prior to recruitment) of the participants, and on medications and nutritional supplements being currently taken by them was obtained and duly recorded.

**Anthropometric and vital signs measurements.** A digital scale, to a precision of 0.1 kg, was used to weigh the subjects, in minimal clothing, while the height of the subjects were recorded to the nearest 0.1 cm. Measurement and recording of blood pressure and pulse was done appropriately by trained study personnel.

**Sample collection and clinical chemistry.** An overnight fasting (11–12 h fasting) blood sample (10 mL) was collected in EDTA (BD Vacutainer®, Becton, Dickinson and Company, Franklin Lakes, NJ) tubes between ~ 0830 and 0930 h by arm (antecubital vein) venipuncture. Four collection time points [T1, T2, T4: 1, 2 and 4 min respectively, after tying the tourniquet, and NT (no tourniquet): collection 5 min after removal of the tourniquet] were included for each study participant.

Samples were transferred immediately and stored in an ice box (< 1.5 h of collection). Post-centrifugation (1166 rcf, 10 min, 4 °C) in a centrifuge (REMI C-23 BL Cooling centrifuge, Mumbai, India), the plasma was aliquoted in cryovials and stored at ~ − 80 °C until analysis. Glucose, total cholesterol, triglycerides and creatinine (Beckman Coulter AU480 Chemistry Analyzer, Beckman Coulter, Brea, CA), insulin (ROCHE Hitachi Elecsys 2010 Chemistry Analyzer, Basel, Switzerland) and haemoglobin A1c (Siemens Dimension Xpand Plus Analyzer, Siemens, Erlangen, Germany) levels were measured using standard plasma and serum clinical chemistry assays.

**High-resolution accurate-mass (HRAM) data analysis.** Plasma samples were processed by following similar protocol as described earlier. Briefly, plasma samples (100 μL) were spiked with an internal standard (IS) of a 1H-labelled amino acid mixture (20 μL, 1 ng/mL; U-1H labelled amino acid mix > 97% purity; Cambridge Isotope Laboratories, Massachusetts, USA) and deproteinised using chilled organic solvent (8:1:1, acetonitrile: methanol: acetone). Samples were vortex-mixed and incubated at 4 °C for 30 min before centrifugation at 20,000 rcf for 20 min in a refrigerated centrifuge (5810 R, Eppendorf, Eppendorf AG, Hamburg, Germany). Supernatants were dried at 40 °C in a vacuum concentrator (Labconco, USA) and dried extracts were reconstituted in acetonitrile/water (1:1). Untargeted metabolomics analysis was performed on a high-resolution accurate-mass (HRAM) platform consisting of an ultra-high pressure liquid chromatograph (UHPLC, Thermo Scientific, Vanquish Flex Binary, Waltham, MA, USA) coupled to an orbitrap based mass spectrometer (Q Exactive, Thermo Scientific, San Jose, USA). The mass spectrometer was calibrated by using a positive ion calibration solution (Pierce LTQ Velos ESI Positive Ion Calibration Solution, ThermoFisher Scientific, Waltham, MA, USA) for positive polarity with an untargeted metabolomics workflow as described earlier. Briefly, plasma samples (100 μL) were spiked with an internal standard (IS) of a 1H-labelled amino acid mixture (20 μL, 1 ng/mL; U-1H labelled amino acid mix > 97% purity; Cambridge Isotope Laboratories, Massachusetts, USA) and deproteinised using chilled organic solvent (8:1:1, acetonitrile: methanol: acetone). Samples were vortex-mixed and incubated at 4 °C for 30 min before centrifugation at 20,000 rcf for 20 min in a refrigerated centrifuge (5810 R, Eppendorf, Eppendorf AG, Hamburg, Germany). Supernatants were dried at 40 °C in a vacuum concentrator (Labconco, USA) and dried extracts were reconstituted in acetonitrile/water (1:1). Untargeted metabolomics analysis was performed on a high-resolution accurate-mass (HRAM) platform consisting of an ultra-high pressure liquid chromatograph (UHPLC, Thermo Scientific, Vanquish Flex Binary, Waltham, MA, USA) coupled to an orbitrap based mass spectrometer (Q Exactive, Thermo Scientific, San Jose, USA). The mass spectrometer was calibrated by using a positive ion calibration solution (Pierce LTQ Velos ESI Positive Ion Calibration Solution, ThermoFisher Scientific, Waltham, MA, USA) on daily basis before starting an analytical sequence consisting of solvent blanks, pooled quality control (QC) samples, which included six technical replicates of a pool of aliquots derived from the study plasma samples and study plasma samples. Separation of the metabolites was achieved by using a Zorbax Eclipse plus-C18 column (150 × 2.1 × 1.8 micron, Agilent Technologies, Santa Clara, CA, USA) maintained at 40 °C. Other LC–MS/MS related method parameters are similar to that described earlier.

Raw data files acquired through the Xcalibur software (version 4.1, ThermoFisher Scientific, MA, USA) were initially processed by using the Compound Discoverer software (version 3.1.0.305, ThermoFisher Scientific, Waltham, MA, USA) for positive polarity with an untargeted metabolomics workflow as described earlier to find and identify the differences between samples. The workflow used the adaptive curve model with 2 min maximum shift, 5 ppm mass tolerance, and 3 S/N (signal/noise) threshold for retention time alignment. Peak detection required less than 5 ppm mass error for extracted ion chromatograms with a minimum peak intensity of 1,000,000. [M + H]+1 was set as base ion with consideration for other adducts. Peaks were required to have a width at half height less than 0.5 min and a minimum of 5 scans. The maximum element count for isotope shift was set to 5. Missing peaks (not detected initially) in a given sample were determined using the Fill Gaps node algorithm with 5 ppm mass error and 1.5 S/N threshold with real
peak detection. The Fill Gaps node calculates the area of missing chromatographic peaks as follows: matching detected ions based on expected m/z and retention time regardless of adduct assignment, re-detecting peaks at lower thresholds, simulating peaks based on expected m/z, and imputing spectrum noise based on detection limit values. Further, QC based area correction is applied for instrument drift using the cubic spline regression model. Each compound was required to be detected in at least 50% of QC runs with a Relative Standard Deviation (RSD) less than 30%. Compound identification was achieved by using mzCloud (ddMS2) and ChemSpider (formula or exact mass) and similarity searches for all compounds with ddMS2 data was done by using mzCloud and mzLogic algorithm applied to rank order ChemSpider results. The pre-processed data were exported to .xlsx files for further statistical analysis.

Statistical analyses. Anthropometric and metabolic profile data were presented as mean ± SD and median with interquartile range (IQR). Metabolite abundance data was scaled using the pareto scaling method and variance of metabolites were decomposed into inter and intra individual variabilities by standard linear random effects model. The proportion of intra-individual variability over total was assessed by Intra-Class Correlation (ICC) for each metabolite. A chi-square test was performed to test whether temporal variability is different from zero within estimation algorithm of random effects model. We considered acceptable false positive rate at most 5%. Further, using the unscaled raw abundance (peak intensities) of the metabolites, the inter individual variabilty of each metabolite at four collection time points were derived by coefficient variation (CV) calculated as the ratio of median absolute deviation (MAD) about median to median of the raw abundance of respective metabolites. The statistical software R version 4.0.2 was used for the analysis (R Core Team, 2020, Vienna, Austria).

Data availability

The datasets generated and analysed during the current study that support the findings of this study are available from the corresponding author on reasonable request.

Received: 2 September 2021; Accepted: 8 December 2021
Published online: 27 December 2021

References

1. Madsen, R., Lundstedt, T. & Trygg, J. Chemometrics in metabolomics—A review in human disease diagnosis. Anal. Chem. Acta 659, 23–33 (2010).
2. Ramautar, R., Berger, R., van der Greef, J. & Hankemeier, T. Human metabolomics: Strategies to understand biology. Curr. Opin. Chem. Biol. 17, 841–846 (2013).
3. Zhang, A., Sun, H. & Wang, X. Serum metabolomics as a novel diagnostic approach for disease: A systematic review. Anal. Bioanal. Chem. 404, 1239–1245 (2012).
4. Gibney, M. J. et al. Metabolomics in human nutrition: Opportunities and challenges. Am. J. Clin. Nutr. 82, 497–503 (2005).
5. Gowda, G. N. et al. Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn. 8, 617–633 (2008).
6. Sterk, B. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910–914 (2009).
7. Kelly, R. S., Vander Heiden, M. G., Giovannucci, E. & Mucci, L. A. Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis, and recurrence. Cancer Epidemiol. Biomark. Prev. 25, 887–906 (2016).
8. Stevens, V. L., Hoover, E., Wang, Y. & Zanetti, K. A. Pre-analytical factors that affect metabolite stability in human urine, plasma, and serum: A review. Metabolites 9, 156 (2019).
9. Yen, P., Lehmann, R. & Xu, G. Effects of pre-analytical processes on blood samples used in metabolomics studies. Anal. Bioanal. Chem. 407, 4879–4892 (2015).
10. Bervoets, L. et al. Influence of preanalytical sampling conditions on the 1H NMR metabolic profile of human blood plasma and introduction of the Standard PREnalalytical Code used in biobanking. Metabolomics 11, 1197–1207 (2015).
11. Kamlage, B. et al. Impact of prolonged blood incubation and extended serum storage at room temperature on the human serum metabolome. Metabolites 8, 6 (2018).
12. Kamlange, B. et al. Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. Clin. Chem. 60, 399–412 (2014).
13. Augeusop, I., Musholt, P. B., Klaus, B., Hightower, K. & Kannt, A. Short-term variability of the human urinary metabolome in a tightly controlled study. Metabolomics 60, 399–412 (2014).
14. PubChem. Sesamex (PubChem). https://pubchem.ncbi.nlm.nih.gov/compound/Sesamex. (Accessed 28 July 2021)
15. PubChem. ValdecoXil (PubChem). https://pubchem.ncbi.nlm.nih.gov/compound/ValdecoXil. (Accessed 28 July 2021)
16. PubChem. Vanillin (PubChem). https://pubchem.ncbi.nlm.nih.gov/compound/Vanillin. (Accessed 28th July 2021)
17. Chaleckis, R., Murakami, I., Takada, I., Kondoh, H. & Yanagida, M. Individual variability in human blood metabolites identifies age-related differences. Proc. Natl. Acad. Sci. 113, 4252–4259 (2016).
18. Johnson, L. C. et al. The plasma metabolome as a predictor of biological aging in humans. GeroScience 41, 895–906 (2019).
19. Rist, M. J. et al. Metabolite patterns predicting sex and age in participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study. PLoS One 12, e0183228 (2017).
20. Darst, B. F., Koscik, R. L., Hogan, K. J., Johnson, S. C. & Engelman, C. D. Longitudinal plasma metabolomics of aging and sex. Aging (Albany NY). 11, 1262–1282 (2019).
21. Holmes, E. et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453, 396–400 (2008).
22. Bar, N. et al. A reference map of potential determinants for the human serum metabolome. Nature 588, 135–140 (2020).
23. Yap, I. K. S. et al. Metabolome-wide association study identifies multiple biomarkers that discriminate North and South Chinese populations at differing risks of cardiovascular disease: INTERMAP Study. J. Proteome Res. 9, 6647–6654 (2010).
24. Kim, K. et al. Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment. PLoS ONE 9, e86223 (2014).
25. Devi, S. et al. Acyl ethanolamides in diabetes and diabetic nephropathy: Novel targets from untargeted plasma metabolomic profiles of South Asian Indian men. Sci. Rep. 9, 18117 (2019).
26. Sangster, T., Major, H., Plumb, R., Wilson, A. J. & Wilson, I. D. A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst. 131, 1075–1078 (2006).
Acknowledgements

The contribution of senior laboratory technicians Mr. Charles Milton and Mr. Kashiraya is gratefully acknowledged.

Author contributions

The authors' individual contributions towards the manuscript are as follows—S.D., A.M. and A.V.K.: designed the research; S.D., R.M.P. and N.N.: conduct of the study; A.M., S.D., S.G. and A.V.K.: analysis of the data, performing statistical analyses and interpretation of the results; All authors critically reviewed the manuscript and read and approved the final version of the manuscript. AM is the guarantor of this work and is responsible for the integrity of the study design.

Funding

This work was supported by the Department of Biotechnology, Government of India [Grant Sanction order BT/PR24342/PFN/20/1314/2017 to AM and AVK] and by the Wellcome Trust/DBT India Alliance Fellowship awarded to AVK [Grant number IA/M/14/1/501681] and to AM [Grant number IA/CPHI/19/1/504593].

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-03665-2.

Correspondence and requests for materials should be addressed to A.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021